Dynamic Changes in Striatal mGluR1 But Not mGluR5 during Pathological Progression of Parkinson's Disease in Human Alpha-Synuclein A53T Transgenic Rats: A Multi-PET Imaging Study

Parkinson's disease (PD) is a prevalent degenerative disorder affecting the CNS that is primarily characterized by resting tremor and movement deficits. Group I metabotropic glutamate receptor subtypes 1 and 5 (mGluR1 and mGluR5, respectively) are important targets for investigation in several CNS disorders. In the present study, we investigated the in vivo roles of mGluR1 and mGluR5 in chronic PD pathology by performing longitudinal positron emission tomography (PET) imaging in A53T transgenic (A53T-Tg) rats expressing an abnormal human α-synuclein (ASN) gene. A53T-Tg rats showed a dramatic decline in general motor activities with age, along with abnormal ASN aggregation and striatal neuron degeneration. In longitudinal PET imaging, striatal nondisplaceable binding potential (BPND) values for [11C]ITDM (N-[4-[6-(isopropylamino) pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methyl-4-[11C]methylbenzamide), a selective PET ligand for mGluR1, temporarily increased before PD symptom onset and dramatically decreased afterward with age. However, striatal BPND values for (E)-[11C]ABP688 [3-(6-methylpyridin-2-ylethynyl)-cyclohex-2-enone-(E)-O-[11C]methyloxime], a specific PET ligand for mGluR5, remained constant during experimental terms. The dynamic changes in striatal mGluR1 BPND values also showed a high correlation in pathological decreases in general motor activities. Furthermore, declines in mGluR1 BPND values were correlated with decreases in BPND values for [18F]FE-PE2I [(E)-N-(3-iodoprop-2E-enyl)-2β-carbo-[18F]fluoroethoxy-3β-(4-methylphenyl) nortropane], a specific PET ligand for the dopamine transporter, a biomarker for dopaminergic neurons. In conclusion, our results have demonstrated for the first time that dynamic changes occur in mGluR1, but not mGluR5, that accompany pathological progression in a PD animal model. SIGNIFICANCE STATEMENT Synaptic signaling by glutamate, the principal excitatory neurotransmitter in the brain, is modulated by group I metabotropic glutamate receptors, including the mGluR1 and mGluR5 subtypes. In the brain, mGluR1 and mGluR5 have distinct functional roles and regional distributions. Their roles in brain pathology, however, are not well characterized. Using longitudinal PET imaging in a chronic rat model of PD, we demonstrated that expression of mGluR1, but not mGluR5, dynamically changed in the striatum accompanying pathological PD progression. These findings imply that monitoring mGluR1 in vivo may provide beneficial information to further understand central nervous system disorders.

[1]  Á. Simonyi,et al.  Expression of groups I and II metabotropic glutamate receptors in the rat brain during aging , 2005, Brain Research.

[2]  J. Maeda,et al.  Development of N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methyl-4-[11C]methylbenzamide for positron emission tomography imaging of metabotropic glutamate 1 receptor in monkey brain. , 2012, Journal of medicinal chemistry.

[3]  M. Croucher,et al.  Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6‐hydroxydopamine toxicity in vivo , 2007, Journal of neurochemistry.

[4]  Y. Okubo,et al.  In vivo activity of modafinil on dopamine transporter measured with positron emission tomography and [¹⁸F]FE-PE2I. , 2014, The international journal of neuropsychopharmacology.

[5]  Seiji Tamura,et al.  Neuroprotective effects of the selective type 1 metabotropic glutamate receptor antagonist YM-202074 in rat stroke models , 2008, Brain Research.

[6]  C. Halldin,et al.  Reproducibility of PET measurement for presynaptic dopaminergic functions using L-[&bgr;-11C]DOPA and [18F]FE-PE2I in humans , 2014, Nuclear medicine communications.

[7]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[8]  T. Dawson,et al.  Differential localization of phosphoinositide-linked metabotropic glutamate receptor (mGluR1) and the inositol 1,4,5-trisphosphate receptor in rat brain , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[9]  S. Nakanishi,et al.  Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction. , 1992, The Journal of biological chemistry.

[10]  David R. Brown,et al.  Seeking a Mechanism for the Toxicity of Oligomeric α-Synuclein , 2015, Biomolecules.

[11]  Age‐related decline in the functional response of striatal group I mGlu receptors , 2000, Neuroreport.

[12]  M. Rice,et al.  Mobilization of Calcium from Intracellular Stores Facilitates Somatodendritic Dopamine Release , 2009, The Journal of Neuroscience.

[13]  S. Nakanishi,et al.  Signal transduction and pharmacological characteristics of a metabotropic glutamate receptor, mGluRl, in transfected CHO cells , 1992, Neuron.

[14]  A. Aliaga,et al.  In vivo and in vitro Validation of Reference Tissue Models for the mGluR5 Ligand [11C]ABP688 , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[15]  D. Standaert,et al.  Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[16]  A. Brownell,et al.  Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease , 2010, Neuroscience Letters.

[17]  M. Amalric,et al.  Metabotropic Glutamate Receptors 5 Blockade Reverses Spatial Memory Deficits in a Mouse Model of Parkinson's Disease , 2009, Neuropsychopharmacology.

[18]  Yuichiro Yoshida,et al.  Visualization of early infarction in rat brain after ischemia using a translocator protein (18kDa) PET ligand [11C]DAC with ultra-high specific activity , 2011, NeuroImage.

[19]  Takaaki AbeS,et al.  Molecular Characterization of a Novel Metabotropic Glutamate Receptor mGluR 5 Coupled to Inositol Phosphate / Ca 2 + Signal Transduction , 2001 .

[20]  T. Himi,et al.  Reduced expression of the molecular markers of dopaminergic neuronal atrophy in the aging rat brain. , 1995, The journals of gerontology. Series A, Biological sciences and medical sciences.

[21]  R. Wurtman,et al.  Metabotropic glutamate receptor agonists increase release of soluble amyloid precursor protein derivatives from rat brain cortical and hippocampal slices. , 1997, The Journal of pharmacology and experimental therapeutics.

[22]  R. Sanchez-Pernaute,et al.  Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates , 2008, NeuroImage.

[23]  K. Fuxe,et al.  Group I mGluR antagonist AIDA protects nigral DA cells from MPTP-induced injury , 2001, Neuroreport.

[24]  Qin Li,et al.  A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys , 2010, Neurobiology of Disease.

[25]  R. Duvoisin,et al.  Role of the Second and Third Intracellular Loops of Metabotropic Glutamate Receptors in Mediating Dual Signal Transduction Activation* , 1998, The Journal of Biological Chemistry.

[26]  D. Watanabe,et al.  Glutamate receptors: brain function and signal transduction 1 Published on the World Wide Web on 21 October 1997. 1 , 1998, Brain Research Reviews.

[27]  L. Grégoire,et al.  mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys , 2008, Neurobiology of Aging.

[28]  Mark E. Schmidt,et al.  N-Acetylcysteine– and MK-801–Induced Changes in Glutamate Levels Do Not Affect In Vivo Binding of Metabotropic Glutamate 5 Receptor Radioligand 11C-ABP688 in Rat Brain , 2013, The Journal of Nuclear Medicine.

[29]  F. Cicchetti,et al.  Modulation of Dopaminergic and Glutamatergic Brain Function: PET Studies on Parkinsonian Rats , 2007, Journal of Nuclear Medicine.

[30]  J. Schiefer,et al.  The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease , 2004, Brain Research.

[31]  L. Crepaldi,et al.  Metabotropic Glutamate 1 Receptor: Current Concepts and Perspectives , 2008, Pharmacological Reviews.

[32]  D. Ros,et al.  Dopamine transporter imaging in the aged rat: a [¹²³I]FP-CIT SPECT study. , 2015, Nuclear medicine and biology.

[33]  Fumitoshi Kodaka,et al.  Quantification of Dopamine Transporter in Human Brain Using PET with 18F-FE-PE2I , 2012, The Journal of Nuclear Medicine.

[34]  N. Volkow,et al.  Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[35]  F. Tang,et al.  Two-methyl-6-phenylethynyl-pyridine (MPEP), a metabotropic glutamate receptor 5 antagonist, with low doses of MK801 and diazepam: A novel approach for controlling status epilepticus , 2007, Neuropharmacology.

[36]  H. Kita,et al.  Down‐regulation of metabotropic glutamate receptor 1α in globus pallidus and substantia nigra of parkinsonian monkeys , 2005, The European journal of neuroscience.

[37]  C. Halldin,et al.  Synthesis, radiolabeling and preliminary in vivo evaluation of [18F]FE-PE2I, a new probe for the dopamine transporter. , 2009, Bioorganic & medicinal chemistry letters.

[38]  M. Croucher,et al.  Additive neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson's model , 2008, Neuroreport.

[39]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[40]  A. Singleton,et al.  How genetics research in Parkinson's disease is enhancing understanding of the common idiopathic forms of the disease , 2005, Current opinion in neurology.

[41]  W. Danysz,et al.  Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease , 2006, Brain Research Bulletin.

[42]  A. Kawanami,et al.  Accumulation of α-Synuclein Triggered by Presynaptic Dysfunction , 2012, The Journal of Neuroscience.

[43]  W. Löscher,et al.  mGlu1 and mGlu5 receptor antagonists lack anticonvulsant efficacy in rodent models of difficult-to-treat partial epilepsy , 2006, Neuropharmacology.

[44]  Lin Xie,et al.  Noninvasive Quantification of Metabotropic Glutamate Receptor Type 1 with [11C]ITDM: a Small-Animal PET Study , 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[45]  Greg A. Gerhardt,et al.  Decreased plasma membrane expression of striatal dopamine transporter in aging , 2003, Neurobiology of Aging.

[46]  F. Tortella,et al.  Selective mGluR5 receptor antagonist or agonist provides neuroprotection in a rat model of focal cerebral ischemia , 2001, Brain Research.

[47]  Hyejin Kang,et al.  In Vivo Imaging of mGluR5 Changes during Epileptogenesis Using [11C]ABP688 PET in Pilocarpine-Induced Epilepsy Rat Model , 2014, PloS one.

[48]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[49]  D. Wong,et al.  Dose‐dependent, saturable occupancy of the metabotropic glutamate subtype 5 receptor by fenobam as measured with [11C]ABP688 PET imaging , 2014, Synapse.

[50]  Ming-Rong Zhang,et al.  Binding potential of (E)-[¹¹C]ABP688 to metabotropic glutamate receptor subtype 5 is decreased by the inclusion of its ¹¹C-labelled Z-isomer. , 2014, Nuclear medicine and biology.